Erratum to “Unexpected High Response Rate to Traditional Therapy after Dendritic Cell-Based Vaccine in Advanced Melanoma: Update of Clinical Outcome and Subgroup Analysis”

Documenti analoghi

• Unexpected High Response Rate to Traditional Therapy after Dendritic Cell-Based Vaccine in Advanced Melanoma: Update of Clinical Outcome and Subgroup Analysis
  di: Ridolfi, Laura, et al.
  Pubblicazione: (2010)
• Improved overall survival in dendritic cell vaccination-induced immunoreactive subgroup of advanced melanoma patients
  di: Ridolfi, Ruggero, et al.
  Pubblicazione: (2006)
• Low-dose temozolomide before dendritic-cell vaccination reduces (specifically) CD4(+)CD25(++)Foxp3(+) regulatory T-cells in advanced melanoma patients
  di: Ridolfi, Laura, et al.
  Pubblicazione: (2013)
• FRET microscopy autologous tumor lysate processing in mature dendritic cell vaccine therapy
  di: Fiammenghi, Laura, et al.
  Pubblicazione: (2010)
• Vaccination with autologous dendritic cells loaded with autologous tumor lysate or homogenate combined with immunomodulating radiotherapy and/or preleukapheresis IFN-α in patients with metastatic melanoma: a randomised “proof-of-principle” phase II study
  di: de Rosa, Francesco, et al.
  Pubblicazione: (2014)